1. Home
  2. SY vs HURA Comparison

SY vs HURA Comparison

Compare SY & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SY

So-Young International Inc. American Depository Shares

HOLD

Current Price

$2.16

Market Cap

192.7M

Sector

Technology

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.13

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SY
HURA
Founded
2013
2009
Country
China
United States
Employees
N/A
22
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
192.7M
160.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
SY
HURA
Price
$2.16
$2.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.50
$9.50
AVG Volume (30 Days)
205.3K
252.3K
Earning Date
05-15-2026
05-15-2026
Dividend Yield
0.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$38.64
N/A
Revenue Next Year
$30.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.28
$0.41
52 Week High
$5.35
$3.90

Technical Indicators

Market Signals
Indicator
SY
HURA
Relative Strength Index (RSI) 64.48 44.17
Support Level $1.68 $2.11
Resistance Level $2.15 $2.20
Average True Range (ATR) 0.16 0.10
MACD 0.03 -0.01
Stochastic Oscillator 80.46 39.34

Price Performance

Historical Comparison
SY
HURA

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: